These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32715723)

  • 1. New Therapeutic Targets and Treatment Options for Thrombotic Microangiopathy: Caplacizumab and Ravulizumab.
    Chung C
    Ann Pharmacother; 2021 Mar; 55(3):330-343. PubMed ID: 32715723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura.
    Gómez-Seguí I; Fernández-Zarzoso M; de la Rubia J
    Expert Rev Hematol; 2020 Nov; 13(11):1153-1164. PubMed ID: 32876503
    [No Abstract]   [Full Text] [Related]  

  • 3. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Knöbl P; Cataland S; De Beuf K; Callewaert F; De Winter H; Zeldin RK
    J Thromb Haemost; 2017 Jul; 15(7):1448-1452. PubMed ID: 28445600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
    Hollifield AL; Arnall JR; Moore DC
    Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.
    Knoebl P; Cataland S; Peyvandi F; Coppo P; Scully M; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Minkue Mi Edou J; De Winter H; Callewaert F
    J Thromb Haemost; 2020 Feb; 18(2):479-484. PubMed ID: 31691462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura.
    Elverdi T; Eskazan AE
    Drug Des Devel Ther; 2019; 13():1251-1258. PubMed ID: 31118566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
    Scully M; Cataland SR; Peyvandi F; Coppo P; Knöbl P; Kremer Hovinga JA; Metjian A; de la Rubia J; Pavenski K; Callewaert F; Biswas D; De Winter H; Zeldin RK;
    N Engl J Med; 2019 Jan; 380(4):335-346. PubMed ID: 30625070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura.
    Sargentini-Maier ML; De Decker P; Tersteeg C; Canvin J; Callewaert F; De Winter H
    Expert Rev Clin Pharmacol; 2019 Jun; 12(6):537-545. PubMed ID: 30977686
    [No Abstract]   [Full Text] [Related]  

  • 9. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
    Peyvandi F; Scully M; Kremer Hovinga JA; Cataland S; Knöbl P; Wu H; Artoni A; Westwood JP; Mansouri Taleghani M; Jilma B; Callewaert F; Ulrichts H; Duby C; Tersago D;
    N Engl J Med; 2016 Feb; 374(6):511-22. PubMed ID: 26863353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis.
    Loscocco GG; Malandrino D; Vannini F; Vinci MC; Di Marzio G; Fallai L; Scappini B
    Transfus Apher Sci; 2021 Feb; 60(1):103010. PubMed ID: 33223471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.
    Goshua G; Sinha P; Hendrickson JE; Tormey C; Bendapudi PK; Lee AI
    Blood; 2021 Feb; 137(7):969-976. PubMed ID: 33280030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caplacizumab for relapsing thrombotic thrombocytopenic purpura.
    Kaczmarek V; Holle J; Astudillo R; Kempf C; Bufler P; Müller D
    Pediatr Nephrol; 2019 Sep; 34(9):1625-1628. PubMed ID: 31177334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Rondeau E; Scully M; Ariceta G; Barbour T; Cataland S; Heyne N; Miyakawa Y; Ortiz S; Swenson E; Vallee M; Yoon SS; Kavanagh D; Haller H;
    Kidney Int; 2020 Jun; 97(6):1287-1296. PubMed ID: 32299680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab.
    Völker LA; Brinkkoetter PT; Knöbl PN; Krstic M; Kaufeld J; Menne J; Buxhofer-Ausch V; Miesbach W
    J Thromb Haemost; 2020 Nov; 18(11):3061-3066. PubMed ID: 32757435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
    Ariceta G; Dixon BP; Kim SH; Kapur G; Mauch T; Ortiz S; Vallee M; Denker AE; Kang HG; Greenbaum LA;
    Kidney Int; 2021 Jul; 100(1):225-237. PubMed ID: 33307104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When to consider targeted therapies in thrombotic microangiopathies in the modern era: walking the tightrope between cost, safety, and efficacy.
    Murphree CR; Olson SR; DeLoughery TG; Shatzel JJ
    J Thromb Thrombolysis; 2020 May; 49(4):602-605. PubMed ID: 32219721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.
    Poullin P; Bornet C; Veyradier A; Coppo P
    Drugs Today (Barc); 2019 Jun; 55(6):367-376. PubMed ID: 31250841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis.
    Gäckler A; Schönermarck U; Dobronravov V; La Manna G; Denker A; Liu P; Vinogradova M; Yoon SS; Praga M
    BMC Nephrol; 2021 Jan; 22(1):5. PubMed ID: 33407224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura.
    Bergstrand M; Hansson E; Delaey B; Callewaert F; De Passos Sousa R; Sargentini-Maier ML
    J Clin Pharmacol; 2022 Mar; 62(3):409-421. PubMed ID: 34699078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod A; Veyradier A; Coppo P
    J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.